O'Neal D, Hew F L, Sikaris K, Ward G, Alford F, Best J D
University of Melbourne, Department of Medicine, St. Vincent's Hospital, Fitzroy, Australia.
J Clin Endocrinol Metab. 1996 Jul;81(7):2448-54. doi: 10.1210/jcem.81.7.8675559.
Adults receiving conventional replacement therapy for hypopituitarism are known to have increased cardiovascular mortality. The aim of this study was to assess the lipid profiles of 30 hypopituitary adults compared with 2 case control groups, 1 matched for age, sex, and body mass index (BMI) and the second matched for age and sex only with a BMI representative of the general population. Fasting lipids, lipoproteins, and apoproteins (Apo) were determined by routine methods. Low density lipoprotein (LDL) particle size was determined by nondenaturing gradient gel electrophoresis. LDL size was significantly smaller in the hypopituitary group (25.9 +/- 0.1 nm) than in the BMI-matched (26.2 +/- 0.1 nm; P < 0.05) and standard control (26.3 +/- 0.1 nm; P < 0.01) groups. High density lipoprotein cholesterol levels in the hypopituitary group were significantly lower than those in the BMI-matched control group (1.13 +/- 0.06 vs. 1.34 +/- 0.06 mmol/L; P < 0.05) and the standard control group (1.38 +/- 0.06 mmol/L; P < 0.005). Apo A1 levels were also lower compared with those in the BMI-matched (122 +/- 6 vs. 137 +/- 4 mg/dL; P < 0.05) and the standard (143 +/- 4 mg/dL; P < 0.005) control groups. There was a trend toward higher triglyceride levels when the hypopituitary subjects were compared with the standard control group [1.4 (95% CI, 1.3-2.2) vs. 1.0 (95% CI, 0.9-1.4) mmol/L; P = 0.06]. These differences were more marked in the female subjects studied. No significant differences were noted in total cholesterol, LDL cholesterol, or Apo B levels. We conclude that hypopituitary patients receiving conventional replacement therapy have an atherogenic lipid profile characterized by small dense LDL, decreased high density lipoprotein cholesterol, and increased triglyceride levels, which may contribute to the excess cardiovascular mortality in this group.
已知接受传统垂体功能减退替代疗法的成年人心血管死亡率会升高。本研究的目的是评估30名垂体功能减退成年人的血脂谱,并与2个病例对照组进行比较,其中1个对照组在年龄、性别和体重指数(BMI)方面匹配,另一个对照组仅在年龄和性别方面匹配,其BMI代表一般人群。通过常规方法测定空腹血脂、脂蛋白和载脂蛋白(Apo)。通过非变性梯度凝胶电泳测定低密度脂蛋白(LDL)颗粒大小。垂体功能减退组的LDL大小(25.9±0.1纳米)明显小于BMI匹配组(26.2±0.1纳米;P<0.05)和标准对照组(26.3±0.1纳米;P<0.01)。垂体功能减退组的高密度脂蛋白胆固醇水平明显低于BMI匹配对照组(1.13±0.06对1.34±0.06毫摩尔/升;P<0.05)和标准对照组(1.38±0.06毫摩尔/升;P<0.005)。与BMI匹配组(122±6对137±4毫克/分升;P<0.05)和标准对照组(143±4毫克/分升;P<0.005)相比,Apo A1水平也较低。与标准对照组相比,垂体功能减退受试者的甘油三酯水平有升高趋势[1.4(95%CI,1.3 - 2.2)对1.0(95%CI,0.9 - 1.4)毫摩尔/升;P = 0.06]。这些差异在研究的女性受试者中更为明显。总胆固醇、LDL胆固醇或Apo B水平未观察到显著差异。我们得出结论,接受传统替代疗法的垂体功能减退患者具有致动脉粥样硬化的血脂谱,其特征为小而密的LDL、高密度脂蛋白胆固醇降低和甘油三酯水平升高,这可能是该组心血管死亡率过高的原因。